Patents Examined by Noble E Jarrell
  • Degraders and Degrons for targeted protein degradation
    Patent number: 11524949
    Abstract: Pharmaceutical Degraders and Degrons for use in therapeutic applications are described herein.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: December 13, 2022
    Assignee: C4 Therapeutics, Inc.
    Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Minsheng He, Kiel Lazarski
  • Bis-amines, compositions, and uses related to CXCR4 inhibition
    Patent number: 11517565
    Abstract: This disclosure relates bis-amine compounds disclosed herein and uses related to CXCR4 inhibition. In certain embodiments, the compounds have formula I, salts, derivatives, and prodrugs thereof wherein, A is an bridging aryl or heterocyclyl and R1 and R2 are further disclosed herein. In certain embodiments, the disclosure contemplates pharmaceutical compositions comprising compounds disclosed herein. In certain embodiments, the disclosure relates to methods of treating or preventing CXCR4 related diseases or conditions by administering an effective amount of a compound disclosed herein to a subject in need thereof.
    Type: Grant
    Filed: June 18, 2020
    Date of Patent: December 6, 2022
    Assignees: Emory University, Georgia State University Research Foundation, Inc.
    Inventors: Hyunsuk Shim, Suazette Reid Mooring, Renren Bai
  • Quinazolines compound, preparation method therefor and application thereof
    Patent number: 11504371
    Abstract: The present invention discloses a compound of anilino polyethylene glycol ether cycloquinazoline substituted with a substituted arylmethyl heteroatomic group having the structure of formula (I) below, or a pharmaceutically acceptable salt, ester or solvate thereof, and a pharmaceutical composition comprising the same. The compound and pharmaceutical composition disclosed herein can be used in tumor targeted therapy and in the regulation of tumors and related diseases.
    Type: Grant
    Filed: March 12, 2020
    Date of Patent: November 22, 2022
    Assignee: BEIJING NORMAL UNIVERSITY
    Inventor: Chuanmin Qi
  • Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
    Patent number: 11505555
    Abstract: This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a ?5-containing GABAA receptor agonist (e.g.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: November 22, 2022
    Assignee: AGENEBIO, INC.
    Inventors: Belew Mekonnen, John A. Butera, Jianxing Huang, Hemantbhai Patel
  • Methods and materials for treating cancer
    Patent number: 11497729
    Abstract: This document provides methods and materials involved in treating cancer. For example, methods and materials for using an inhibitor of USP7 polypeptide to increase the sensitivity of cancer cells (e.g., CD340+ cancer cells such as HER2+ cancer cells) to treatment with an inhibitor of a CD340 polypeptide (e.g., an inhibitor of a HER2 polypeptide) are provided. Methods and materials for using USP7 polypeptide inhibitors in combination with CD340 polypeptide inhibitors to treat cancer (e.g., HER2+ breast cancer that was refractory to trastuzumab alone treatment) are provided.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: November 15, 2022
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Liewei Wang, Matthew P. Goetz, Judy C. Boughey, Jia Yu, Bo Qin
  • Di-substituted pyrazole compounds for the treatment of diseases
    Patent number: 11497738
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds and compositions in treating a condition, disease, or disorder associated with abnormal activation of the SREBP pathway, including metabolic disorders such as obesity, cancer, cardiovascular disease, and nonalcoholic fatty liver disease (NAFLD) wherein the compound is according to Formula (I).
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: November 15, 2022
    Assignee: FGH BIOTECH, INC.
    Inventors: Joel Huff, Motonari Uesugi, John Kincaid
  • Compounds and methods useful in the treatment of a PRMT5-mediated disorder
    Patent number: 11485731
    Abstract: The present disclosure relates to compounds suitable for the inhibition of protein arginine methyl-transferase (PRMT), in particular PRMT5. These compounds may be for use as therapeutic agents, in particular, agents for use in the treatment and/or prevention of proliferative diseases, such as cancer.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: November 1, 2022
    Assignee: ARGONAUT THERAPEUTICS LIMITED
    Inventors: Andrew Morley, Rebecca Miller, Nicholas La Thangue
  • Compositions and methods for the treatment of fungal infections
    Patent number: 11485730
    Abstract: The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX or Formula X and, the methods for the treatment of fungal infections may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fungal infections.
    Type: Grant
    Filed: January 10, 2022
    Date of Patent: November 1, 2022
    Assignee: Cellix Bio Private Limited
    Inventor: Mahesh Kandula
  • Inhibitors of short-chain dehydrogenase activity for promoting neurogenesis and inhibiting nerve cell death
    Patent number: 11478458
    Abstract: A method of promoting neuroprotection in a subject from axonal degeneration, neuronal cell death, and/or glia cell damage after injury, augmenting neuronal signaling underlying learning and memory, stimulating neuronal regeneration after injury, and/or treating a disease, disorder, and/or condition of the nervous system in a subject in need thereof includes administering to the subject a therapeutically effective amount of a 15-PGDH inhibitor.
    Type: Grant
    Filed: August 18, 2020
    Date of Patent: October 25, 2022
    Assignees: CASE WESTERN RESERVE UNIVERSITY, BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, THE UNIVERSITY OF IOWA
    Inventors: Sanford Markowitz, Joseph Ready, Andrew Pieper
  • IgG-binding peptide, and specific modification of antibody with said peptide
    Patent number: 11472865
    Abstract: It is an object of the present invention to provide a method for modifying an antibody in a specific and simple manner, and others. The present invention relates to: an IgG-binding peptide, an IgG-binding peptide modified with a crosslinking agent, a complex of an IgG-binding peptide modified with the crosslinking agent and IgG, a method for producing the complex, and others.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: October 18, 2022
    Assignee: Kagoshima University
    Inventor: Yuji Ito
  • Phthalocyanine dye compounds, conjugates and methods of use thereof
    Patent number: 11466158
    Abstract: Disclosed herein are phthalocyanine dyes, and conjugates thereof, useful as fluorescent reporters for bioassays, for optical imaging and as therapeutic conjugates as the photosensitizing agents in light-based therapies including photoimmuno therapy (PIT). Certain phthalocyanine dyes disclosed herein are water soluble, and possess photophysical and photochemical profiles useful for use in imaging or therapy.
    Type: Grant
    Filed: September 22, 2021
    Date of Patent: October 11, 2022
    Assignee: RAKUTEN MEDICAL, INC.
    Inventors: Juan Betancort, Lew Makings, Torsten Wiemann
  • Methods and compositions relating to adjuvants
    Patent number: 11464854
    Abstract: The methods and compositions described herein relate to methods of immunization or stimulating an immune response, e.g., using agonists of TLR7 and/or TLR8 as antigens. The methods and compositions described herein have particular relevance to use in infants.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: October 11, 2022
    Assignees: Children's Medical Center Corporation, University of Montana
    Inventors: Ofer Levy, David Dowling, Helene Bazin-Lee, David Burkhart, Jay Evans, Alyson Jessica Smith
  • Carcinogenesis inhibitor
    Patent number: 11464762
    Abstract: A carcinogenesis inhibitor having no side effect and having an excellent effect by oral administration. A carcinogenesis inhibitor containing a hydantoin derivative or a pharmaceutically acceptable salt thereof as an active ingredient shows an inhibiting action for polyp formation and for cell proliferation, and has no side effect and highly safe whereby it is very highly useful as a pharmaceutical agent and a food such as supplement which prevent the occurrence and progress of cancer, inhibits the recurrence and metastasis of cancer and further achieves the therapeutic effect.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: October 11, 2022
    Assignees: NATIONAL CANCER CENTER, NIPPON ZOKI PHARMACEUTICAL CO., LTD.
    Inventors: Michihiro Mutoh, Yurie Kurokawa, Gen Fujii, Shingo Miyamoto
  • Di-macrocycles
    Patent number: 11453652
    Abstract: The invention relates to chemical compounds and complexes that can be used in therapeutic and diagnostic applications.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: September 27, 2022
    Assignee: LUMIPHORE, INC.
    Inventors: Darren Magda, Jide Xu, Nathaniel G. Butlin
  • Maytansinoid derivatives, conjugates thereof, and methods of use
    Patent number: 11446389
    Abstract: Provided herein are maytansinoid compounds, derivatives thereof, conjugates thereof, and methods of treating or preventing proliferative diseases with the same.
    Type: Grant
    Filed: October 24, 2019
    Date of Patent: September 20, 2022
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Thomas Nittoli, Thomas P. Markotan
  • Composition, photoelectric conversion element, and imaging device
    Patent number: 11447639
    Abstract: A composition contains a phthalocyanine derivative represented by the following formula: where R1 to R8 are independently an alkyl group, M is Si, each of R9 and R10 is any one of substituents represented by the following formulas, R11 to R13 are independently an alkyl group, and R14 to R18 are independently an alkyl group or an aryl group:
    Type: Grant
    Filed: September 7, 2020
    Date of Patent: September 20, 2022
    Assignee: PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD.
    Inventors: Hiroaki Iijima, Masaya Hirade, Manabu Nakata, Taniyuki Furuyama
  • Phospholipid ether analogs as cancer-targeting drug vehicles
    Patent number: 11439709
    Abstract: The present invention is directed to therapeutic compounds capable of targeting cancer cells and cancer stem cells. The present invention is further directed to compositions comprising these therapeutic compounds and methods of treating cancer comprising administering these therapeutic compounds.
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: September 13, 2022
    Assignee: Cellectar Biosciences, Inc.
    Inventors: Jamey P. Weichert, Anatoly Pinchuk, Kevin Kozak, Marc Longino, Joseph Grudzinski, Benjamin Titz, Chorom Pak, Nathan Stehle
  • Method for improving or enhancing cognition
    Patent number: 11433057
    Abstract: Disclosed herein are a method for improving cognition in an individual having findings consistent with a cognitive impairment, and a method of enhancing cognition in an individual. The methods include administering a therapeutically effective amount of (R)-3-(6-p-tolyl-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane or a metabolite or a pharmaceutically acceptable salt thereof to the individual.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: September 6, 2022
    Assignee: Vanda Pharmaceuticals Inc.
    Inventor: Mihael H. Polymeropoulos
  • Selective ligands for tau aggregates
    Patent number: 11434237
    Abstract: The invention provides compounds of formula (I) and compositions comprising compounds of formula (I). The invention further provides uses of the compounds of formula (I) and compositions comprising compounds of formula (I), including the use of such compounds for the detection of tau deposits, and the use of such compounds and compositions as diagnostic agents in the diagnosis or monitoring of the progression of a disease or disorder such as Alzheimer's disease or corticobasal degeneration, or for the prevention or treatment of a disease or disorder such as Alzheimer's disease or corticobasal degeneration.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: September 6, 2022
    Assignee: KARIN & STEN MORTSTEDT CBD SOLUTIONS AB
    Inventors: Peter Nilsson, Hamid Shirani
  • Pesticidally active heterocyclic derivatives with sulfur containing substituents
    Patent number: 11413291
    Abstract: Compounds of formula I (I), wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as pesticides and can be prepared in a manner known per se.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: August 16, 2022
    Assignee: SYNGENTA PARTICIPATIONS AG
    Inventors: Sebastian Rendler, Andrew Edmunds, Michel Muehlebach, Girish Rawal, Indira Sen, Vikas Sikervar, Daniel Emery